Innovation Pharmaceuticals Completes Gastric Fluid Testing of Brilacidin Supporting Development of an Oral Dosage Form to Treat Inflammatory Bowel Disease

World News: . []

BEVERLY, Mass., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders the Company has completed early testing evaluating the stability of Brilacidin, its novel defensin-mimetic drug candidate, in simulated gastric fluid—a synthetic form of the fluid found in the stomach.

Results showed very minimal degradation of Brilacidin across 4 hours, suggesting that a simple formulation of Brilacidin likely would not be subject to rapid breakdown once in the stomach. This finding should enable initial clinical testing with a simple formulation of the drug candidate delivered to the gut while a more elegant, tailored oral dosage form of Brilacidin is developed and refined, in parallel. The end goal would be to release Brilacidin selectively in the GI tract via targeted delivery technology.

“These gastric testing results are an important initial step in determining Brilacidin’s likely stability profile with simple oral delivery to the gut,” commented Francis A. Farraye, MD, MSc, Clinical Director, Section of Gastroenterology at Boston Medical Center, Professor of Medicine at Boston University School of Medicine and Scientific Advisor to Innovation Pharmaceuticals. “We were pleased to see that Brilacidin maintains ample integrity in simulated gastric fluid long enough to suggest it would allow for intact passage from the stomach into the gut where clinical disease manifests with Inflammatory Bowel Disease (IBD). One of the key advantages of Brilacidin, as a synthetic defensin mimetic, is the robustness of its design, which should help it to withstand potential degradation in the stomach. I very much look forward to working with Innovation as we aim to advance oral Brilacidin further into clinical development for the treatment of IBD.”

Planned next steps in the development of Brilacidin for oral delivery include clinical testing of Brilacidin in healthy volunteers to assess safety and toleration, the pharmacokinetic profile and effects on the gut’s microbiome. Clinical trials in IBD including Ulcerative Colitis and Crohn’s Disease, would then follow.

“This is a significant development for shareholders,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “A safe and effective oral formulation of Brilacidin would represent a substantial market opportunity given the high prevalence of the disease and need for novel IBD treatments. As the Company works on Phase 3 development of Brilacidin for Oral Mucositis, it is concurrently a high priority to keep making progress on the oral version of Brilacidin for IBD.”

INVESTOR AND MEDIA CONTACT Innovation Pharmaceuticals Inc. Leo Ehrlich info@ipharminc.com

More news and information about Innovation Pharmaceuticals, Inc.

Published By:

Globe Newswire: 13:00 GMT Monday 14th January 2019

Published: .

Search for other references to "innovation" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us